While early trials showed that the MAGE-A3 vaccine could induce immune responses and suggest potential survival benefits, Phase III trials in NSCLC failed to significantly improve disease-free survival in MAGE-A3-positive patients, leading to the termination of some studies (43). This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.